<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806503</url>
  </required_header>
  <id_info>
    <org_study_id>CUNR844A2202</org_study_id>
    <nct_id>NCT04806503</nct_id>
  </id_info>
  <brief_title>A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-masked, Multi-center, Dose-ranging Study to Evaluate the Safety, and Efficacy of UNR844 in Subjects With Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of safety and efficacy of UNR844 in subjects with presbyopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, double-masked, placebo-controlled, randomized, parallel-group study.&#xD;
      The total duration of the study is approximately 13 months. Approximately 225 presbyopic&#xD;
      participants will be enrolled into the study.&#xD;
&#xD;
      Presbyopic participants aged 45 to 55 years are the primary age group in this study.&#xD;
&#xD;
      Screening and Baseline: Participants will be screened for eligibility followed by a baseline&#xD;
      visit after which they will be randomized to receive either UNR844 (low, medium 1, medium 2,&#xD;
      and high) or Placebo, dosed one drop in each eye twice daily, for 3 months and then will&#xD;
      undergo a 9 month treatment holiday period.&#xD;
&#xD;
      Randomized subjects will attend the following study visits after baseline: at Week 2, Month&#xD;
      1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11&#xD;
      and Month 12.&#xD;
&#xD;
      The primary objective for the study is to characterize dose-response of UNR844 for change&#xD;
      from baseline in binocular DCNVA at Month 3.&#xD;
&#xD;
      There are 3 secondary objectives:&#xD;
&#xD;
        1. Characterize dose response of UNR844 as measured by change from baseline in monocular&#xD;
           DCNVA at Month 3&#xD;
&#xD;
        2. Assess the duration of effect using change in DCNVA after Month 3 with various dose&#xD;
           concentrations of UNR844&#xD;
&#xD;
        3. Evaluate the efficacy of improving DCNVA in presbyopic participants, as measured by&#xD;
           proportion of participants gaining at least 0.3 logMAR DCNVA at Month 3&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">March 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize dose-response of UNR844 for change from baseline in binocular Distance-corrected Near Visual Acuity (DCNVA) at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Characterize dose-response of UNR844 for change from baseline in binocular DCNVA at Month 3. DCNVA is measured in Logarithm of Minimum Angle of Resolution (logMAR) at 40 cm, with subjects corrected for any distance refractive errors. Low logMAR score represent good vision while a high logMAR score represent bad vision.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize dose response of UNR844 as measured by change from baseline in monocular DCNVA at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Characterize dose response of UNR844 as measured by change from baseline in monocular DCNVA in logMAR, at 40 cm at Month 3. Low logMAR score represent good vision while a high logMAR score represent bad vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the duration of effect using change in DCNVA after Month 3 with various dose concentrations of UNR844</measure>
    <time_frame>Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11 and Month 12</time_frame>
    <description>Binocular and monocular DCNVA measured in logMAR, at 40 cm monthly after treatment cessation at Month3. Low logMAR score represent good vision while a high logMAR score represent bad vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of improving DCNVA in presbyopic participants, as measured by proportion of participants gaining at least 0.3 logMAR DCNVA at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Proportion of participants gaining at least 0.3 logMAR in binocular and monocular DCNVA compared to baseline at Month 3. DCNVA is measured in Logarithm of Minimum Angle of Resolution (logMAR) at 40 cm, with subjects corrected for any distance refractive errors. Low logMAR score represent good vision while a high logMAR score represent bad vision.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>UNR844 Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UNR844 Low ophthalmic solution; one drop twice-a-day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UNR844 Medium 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UNR844 Medium 1 ophthalmic solution; one drop twice-a-day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UNR844 Medium 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UNR844 Medium 2 ophthalmic solution; one drop twice-a-day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UNR844 High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UNR844 High ophthalmic solution; one drop twice-a-day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Ophthalmic Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo ophthalmic solution; one drop twice-a-day for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UNR844</intervention_name>
    <description>Ophthalmic solution for topical ocular administration</description>
    <arm_group_label>UNR844 High</arm_group_label>
    <arm_group_label>UNR844 Low</arm_group_label>
    <arm_group_label>UNR844 Medium 1</arm_group_label>
    <arm_group_label>UNR844 Medium 2</arm_group_label>
    <other_name>EV06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Ophthalmic Solution</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed&#xD;
&#xD;
          -  Impaired near vision in each eye and when using both eyes, without any near correction&#xD;
&#xD;
          -  Need a certain level of near correction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired distance vision in either eye, with distance correction (if any)&#xD;
&#xD;
          -  Severe short- or long-sightedness&#xD;
&#xD;
          -  Any significant medical or clinical conditions affecting vision, the eyes or general&#xD;
             health&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2A 0K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku ku</city>
        <state>Tokyo</state>
        <zip>160-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>loss of elasticity in lens</keyword>
  <keyword>lens</keyword>
  <keyword>lens disorder</keyword>
  <keyword>loss of near vision</keyword>
  <keyword>Presbyopia</keyword>
  <keyword>UNR844</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

